窄谱中波紫外线联合抗组胺药治疗慢性自发性荨麻疹的疗效观察

目的观察窄谱中波紫外线(NB-UVB)联合抗组胺药治疗慢性自发性荨麻疹的疗效。方法 80例慢性荨麻疹患者,随机分为试验组和对照组,每组各40例。试验组采用NB-UVB光疗,每周2次,共24次,同时口服抗组胺药;对照组仅口服抗组胺药。比较两组治疗后的临床疗效以及随访12周内的复发情况。结果两组患者的症状和体征评分明显下降,且试验组下降更为明显(t=46.37,P0.05)。试验组的临床疗效明显优于对照组(χ~2=6.76,P0.05);且复发率明显低于对照组(χ~2=9.83,P0.01)。结论 NB-UVB安全有效,可作为慢性自发性荨麻疹的辅助治疗手段。     

窄谱中波紫外线治疗白癜风疗效观察

目的：观察窄谱中波紫外线(NB—UVB)N射治疗白癜风的疗效及其影响因素。方法：患者均用白癜酊或复方甘草酸钠霜剂，并内服药物，治疗组109例加用NB—UVB照射治疗，与对照组87例进行比较，根据皮损、照射时间来评价疗效。结果：治疗组有效率为83．49％，明显高于对照组的50．57％；皮损面积小则治疗效果优于面积大者．结论：窄谱NB—UVB照射治疗白癜风，安全有效，不良反心小。     

窄谱中波紫外线治疗银屑病临床观察

目的:应用窄谱中波紫外线(NB-UVB)治疗337例银屑病患者,观察其治疗的有效性及安全性.方法:对银屑病患者进行全身NB-UVB照射,每周3次,应用银屑病皮损面积和严重程度指数(PASI)评分标准进行疗效评价.结果:痊愈所需治疗次数为12～62次,平均治疗次数为29.47次,照射累积剂量为8.24～126.18 J/cm2,平均累积剂量为53.3 J/cm2,未出现严重不良反应.结论:NB-UVB治疗银屑病具有效果好,安全性高的特点.     

窄谱中波紫外线联合阿昔洛韦治疗带状疱疹疗效观察

目的探讨窄谱中波紫外线(NB-UVB)联合阿昔洛韦治疗带状疱疹的临床疗效。方法 58例带状疱疹患者随机分为2组,治疗组采用NB-UVB照射,同时静脉滴注阿昔洛韦、双黄连粉针及口服药物治疗;对照组仅给予静脉滴注及口服药物治疗。根据治疗前、后评分判定疗效指数。结果治疗组痊愈27例、显效5例、有效1例、无效0例,有效率为96.97%;对照组分别为17例、2例、6例、0例,有效率为76.00%。两组有效率比较差异有统计学意义(P0.05),治疗组疗效优于对照组。结论 NB-UVB联合阿昔洛韦治疗带状疱疹安全有效。     

窄谱中波紫外线治疗寻常性银屑病疗效观察

我科于2007年7月～2008年6月采用窄谱中波紫外线(NB-UVB)治疗寻常性银屑病120例,取得满意疗效,现报告如下.     

窄谱中波紫外线治疗白癜风34例疗效观察

目的探讨窄谱中波紫外线（NB-UVB）照射治疗白癜风患者的疗效及其影响因素。方法应用NB-UVB治疗白癜风34例，根据皮损、照射时间来评价疗效。结果痊愈12例，显效16例，好转6例，无效0例，有效率为82.35％，平均总剂量为24.5J／cm^2，达到显效时平均照射20.6次。结论NB-UVB照射治疗白癜风，疗效确切，且不良反应小。     

窄谱中波紫外线治疗白癜风的疗效观察

笔者采用窄谱中波紫外线(narrow band ultravioletB．NBUVB)照射治疗白癜风,取得较好疗效,现报告如下。     

窄谱中波紫外线联合薄芝糖肽治疗白癜风疗效观察

目的观察窄谱中波紫外线(NB-UVB)联合薄芝糖肽治疗白癜风的临床疗效及安全性。方法随机选取120例患者,治疗组60例采用NB-UVB照射治疗,初始剂量为0.4J/cm2,以后每次递增0.1J/cm2,最大剂量<3J/cm2,每周3次,同时肌肉注射薄芝糖肽2mL,隔日1次。3个月为1疗程,1疗程结束后判定疗效。对照组60例单独采用NB-UVB治疗,剂量、用法、疗程同治疗组。结果治疗组有效率为76.67%,对照组为48.33%,两组疗效差异有显著性(P<0.05),120例患者治疗期间均无严重的不良反应。结论NB-UVB联合薄芝糖肽治疗白癜风有效、安全性高。     

窄谱中波紫外线治疗寻常型银屑病临床疗效观察

近10余年来，国外利用窄谱中波紫外线(NB-UVB，波长311～313nm)照射治疗银屑病，该疗法等同或甚至优于补骨脂素长波紫外线(PUVA)的疗效，而且较PUVA安全，因此临床应用日渐增多。为了探索NB-UVB对我国银屑病患者的疗效影响，自2002年10月起，笔者对40例寻常型银屑病患者采用NB-UVB全身照射并进行临床观察，现报告如下。     

中药洗剂联合窄谱中波紫外线治疗手部慢性湿疹疗效观察

目的探讨中药洗剂联合窄谱中波紫外线（NB—UVB）治疗手部慢性湿疹的临床疗效。方法选取受试对象120例，随机分为三组，治疗组予中药洗剂联合NB—UVB治疗，并与单纯NB—UVB照射及中药洗剂治疗作对照，比较各组临床疗效。结果治疗组有效率达93．02％，三组患者有效率比较差异有统计学意义（χ^2=11．93，P〈0．05），治疗组疗效优于两对照组。结论中药洗剂联合窄谱中波紫外线治疗手部慢性湿疹效果满意。     

Comparison of chronic autoimmune urticaria with chronic idiopathic urticaria

BACKGROUND: Chronic urticaria has been described in patients with Helicobacter pylori infection. Despite numerous studies, the correlation between H. pylori infection and chronic urticaria is doubtful. Our study was performed to determine the prevalence of H. pylori infection in autoimmune urticaria and in patients suffering from autoimmune urticaria and autoimmune thyroiditis. METHODS: The authors widely investigated 48 patients. The examinations were extended principally to autologous serum skin test, antithyroid antibodies, and the presence of H. pylori infection as well as detection of antibodies against H. pylori. RESULTS: Out of the 48 patients, 26 were regarded as having autoimmune origin. The prevalence of antithyroid antibodies was different in the two groups of patients with urticaria. There were 11 patients (42.3%) in the autoimmune group compared with three patients (13.6%) in the nonautoimmune group with antithyroid peroxidase antibody (P = 0.03). The difference in the prevalence of H. pylori infection was significant between autoimmune urticaria with and without thyroid autoimmunity (90.9% vs. 46.7%; P = 0.02). Autoimmune thyroiditis was connected with CagA +H. pylori strains, as the H. pylori- specific IgG antibodies revealed significant differences in a prevalence of 120 kDa (P < 0.05). CONCLUSIONS: The authors observed a relationship between autoimmune urticaria and autoimmune thyroiditis. The results strengthen the possibility of cross-reactivity being triggered between CagA plus H. pylori strains and some other organ-specific autoimmune diseases such as autoimmune urticaria and autoimmune thyroiditis. This indicates a possible role of H. pylori in triggering autoimmune urticaria in at least a select group of patients.     

Narrow-band UVB treatment of vitiligo in Chinese

Narrow-band ultraviolet B (NBUVB) phototherapy has recently been reported to be an effective and safe treatment modality for vitiligo. In the present report, we evaluated the efficacy and safety of NBUVB therapy for vitiligo in Chinese patients. Seventy-two vitiligo patients treated from 2000 to 2003, were included retrospectively (male: female=33:39, mean age: 38.5). Among them, 61 were non-segmental type and 11 the segmental type. Treatments were given two to three times a week for a maximum period of one year with an initial dose of 0.2 J/cm2 and a 0-20% increment each session (mean accumulation dose: 155.3 J/cm2). Computer image analysis by Supervise classification was used to estimate the area of vitiligo involvement before and after treatment. An excellent response (75-100% area of repigmentation) was obtained in 9 patients (12.5%) and a good response (50-75%) in 24 (33.3%), a moderate response (25-50%) in 20 (27.8%), and a poor response (0-25%) in 19 (26.4%). In summary, 45.8% of our patients had more than 50% repigmentation. Burns were a side effect in 5 patients (7%) and transient erythema with itching or xerosis was noted in 5 patients (7%). These results indicate that NBUVB phototherapy is an effective and safe treatment choice for generalized vitiligo.     

Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine

BACKGROUND: Antihistamines are the standard treatment for chronic idiopathic urticaria (CIU). For patients whose urticaria is unresponsive to antihistamines, the treatment options are limited. During the previous decade, there have been several case reports demonstrating success with sulfasalazine therapy. In this article, we present a case series evaluating sulfasalazine therapy for antihistamine-unresponsive CIU. OBSERVATIONS: Nineteen patients with antihistamine-unresponsive CIU were treated with sulfasalazine between 2002 and 2005. During sulfasalazine therapy, 14 patients (74%) reported significant improvement, 4 patients (21%) reported minimal improvement but were not satisfied with their symptom relief, and 1 patient (5%) reported a worsening of symptoms. Of the 13 patients who required systemic steroids to control their urticaria, all were able to reduce or discontinue steroid use during sulfasalazine therapy. Although 7 patients (37%) had adverse effects (eg, nausea, headache, mild or transient leukopenia, and transaminitis) that were thought to be caused by the use of sulfasalazine, they all kept taking the drug. CONCLUSIONS: This case series demonstrates that sulfasalazine can be a successful and safe treatment option for patients with CIU who have not responded adequately to treatment with antihistamines. Sulfasalazine was steroid sparing in all subjects who were steroid dependent.     

Review of fexofenadine in the treatment of chronic idiopathic urticaria

Chronic idiopathic urticaria (CIU), characterized by the appearance of itchy wheals of unknown etiology, can be extremely debilitating and can significantly reduce a patient's quality of life (QOL). Fexofenadine, a non-sedating, H1-receptor selective, long-acting antihistamine, is licensed worldwide for the treatment of CIU. A number of dose-ranging studies have evaluated the efficacy and safety of fexofenadine for the the treatment of CIU. In two similar North American studies, patients received either fexofenadine HCI (20, 60, 120, or 240 mg bid) or placebo. All four doses of fexofendine were statistically superior to placebo at reducing pruritus and reducing the number of wheals (P < or = 0.0238). A dose-finding study undertaken in Japanese patients confirmed that fexofenadine HCI (60 mg and 120 mg bid) is an effective treatment for CIU. A similar dose response was shown in all three studies when the results were compared. Furthermore, health outcome analyses of the North American studies indicated that fexofenadine HCI 60 mg bid significantly improved patient's QOL. In these studies, fexofenadine had a consistently comparable safety profile to placebo, with no dose-related trends in the incidence of adverse events. In conclusion, fexofenadine is an effective and well-tolerated treatment for CIU, with a wide therapeutic window. Importantly, the lack of ethnic differences between the studies from North America and Asia indicate that the efficacy and safety of fexofenadine demonstrated in these studies are cross-culturally applicable.     

奥马珠单抗用于治疗难治性慢性特发性荨麻疹

难治性慢性特发性荨麻疹是一种常见的皮肤科疾病,病因不明,对常规治疗反应差,困扰着医生和患者。奥马珠单抗(omalizumab)是一种新型生物制剂,能有效抑制过敏反应,现多应用于治疗哮喘,部分应用于治疗难治性慢性特发性荨麻疹,其疗效得到肯定,也逐渐被皮肤科医师关注和应用。该文综述了奥马珠单抗的作用机制、临床应用、治疗效果和不良反应。     

Narrow-band UVB for the treatment of generalized vitiligo in children

Vitiligo usually begins in childhood with approximately half of the patients manifesting onset of disease prior to the age of 20 years. Treatment options in this age group are few and have disappointing response rates. This study was designed to evaluate the role of narrow-band UVB in the treatment of generalized vitiligo in children. Twenty-six children (aged 5-14 years) with generalized vitiligo (minimal extent of depigmentation of 5% of the skin) were treated three times per week with narrow-band UVB therapy for a maximum period of 1 year. Of 26 patients, 6 were lost to follow up and 20 (7 males, 13 females) completed the study. At the end of 1 year of therapy, 15 (75%) patients developed marked to complete repigmentation. Moderate and mild repigmentation was noted in four (20%) and one (5%) patients, respectively. An average number of 34 (+/- 2) treatment visits was required to achieve 50% repigmentation. Adverse events were mild and transient. Narrow-band UVB is an effective and well-tolerated treatment option for childhood vitiligo.     

咪唑斯汀治疗慢性荨麻疹临床试验

目的:评价咪唑斯汀(mizolastine,皿治林)治疗慢性荨麻疹的疗效和安全性。方法:用多中心、开放性的方法对患者服用咪唑斯汀10mg,每日1次,连续服用14天,进行疗效评价。结果:可分析病例1390例,男性594例,女性796例。治疗第7天,疾病总积分由治疗前的7.7259±0.0379下降为3.1388±0.0605,差异有显著性(P<0.001)。21.7%获痊愈,23.2%获显效,有效率44.8%。治疗第14天时,总积分进一步下降为1.3813±0.0517,与治疗前比较差异有显著性(P<0.001)。54.7%获痊愈,27.2%获显效,有效率81.9%。不良反应发生率为11.3%,均为轻微和可逆性反应。结论:咪唑斯汀治疗慢性荨麻疹疗效肯定,安全性高。